JP Morgan maintains Xencor at Neutral, raises price target to $37 from $21
JP Morgan has maintained its "Neutral" rating on Xencor (XNCR) and significantly increased its price target from $21 to $37, representing a 76.2% rise. This new target suggests a 7.6% upside from the stock's closing price of $34.39 on November 18. Other analysts have recently issued price targets ranging from $40 to $70 for Xencor.
Form 4 Xencor Inc: Richard J. Ranieri (Director) For: 10 November
This article reports on a Form 4 filing for Xencor Inc., indicating that Director Richard J. Ranieri made a transaction on November 10. The filing, published on November 16, 2026, details insider trading activity for the company. Xencor Inc.'s stock (XNCR) was down 2.85% at the time of publication.
Xencor director Richard Ranieri sells $3.19 million in shares
Richard J. Ranieri, a director at Xencor Inc, sold over $3.19 million worth of common stock on November 10, 2026, after exercising stock options worth approximately $1.43 million on the same day. These transactions occurred as Xencor shares traded near their 52-week high, following a significant 148% gain over the past year. Analysts from Truist Securities, Wells Fargo, and RBC Capital have recently raised their price targets for Xencor, reflecting a positive outlook on the company's XmAb819 drug data.
Form 4 Xencor Inc: Richard J. Ranieri (Director) For: 10 November
This article reports on a Form 4 filing for Xencor Inc, specifically detailing an insider transaction by Director Richard J. Ranieri on November 10. The filing, published by Investing.com, provides information about the director's activities related to the company's stock, XNCR.
Form 4 Xencor Inc: Bart Jan Cornelissen (SR. VICE PRESIDENT & CFO) For: 11 November
This article reports a Form 4 filing for Xencor Inc, detailing a transaction by Bart Jan Cornelissen, the company's SR. VICE PRESIDENT & CFO. The filing pertains to activity on November 11. The article simply states the filing information without providing further details about the nature of the transaction.
Trade Alert: Senior VP & CFO Of Xencor Bart Cornelissen Has Sold Stock
Xencor's Senior VP & CFO, Bart Cornelissen, recently sold US$402k worth of shares at an average price of US$39.82, representing a 36% reduction in his holding. This was the largest insider sale in the last year, occurring around the current stock price of US$37.09. Despite the sale, insider ownership remains at 1.2%, suggesting some alignment, though the lack of insider buying and identified warning signs suggest caution for potential investors.
Form 144 Xencor Inc For: 14 November By Investing.com
This article from Investing.com announces the filing of Form 144 for Xencor Inc., related to transactions on November 14th. The brief notice highlights Xencor's stock symbol XNCR, which is noted to be down 2.73%. The main content is the official notification of the Form 144 filing.
Toronto-Dominion Bank and TD Securities report a stake above 5% in Xencor (XNCR).
The Toronto-Dominion Bank and TD Securities Inc. have reported an aggregate beneficial ownership of 3,871,396 shares, or 5.2%, in Xencor Inc. (XNCR) as of September 30, 2026. TD Bank holds sole voting and dispositive power over 3,871,296 shares, while TD Securities holds these powers over 100 shares. This disclosure was made via a Schedule 13G filing with the SEC.
Form 4 Xencor Inc: Bart Jan Cornelissen (SR. VICE PRESIDENT & CFO) For: 11 November
This article reports on a Form 4 filing for Xencor Inc, specifically detailing an insider transaction by Bart Jan Cornelissen, the SR. VICE PRESIDENT & CFO, on November 11th. The filing indicates a significant event related to his holdings or transactions in the company. The specific details of the Form 4 are not elaborated upon in the provided text.
Xencor (NASDAQ:XNCR) Director Sells $3,189,141.00 in Stock
Xencor (NASDAQ:XNCR) Director Richard Ranieri sold 81,252 shares of the company's stock for approximately $3.19 million on November 10th, significantly reducing his stake. The sale comes after Xencor reported strong quarterly earnings, beating analyst estimates with $0.50 EPS and $116.52 million in revenue. Despite a "Moderate Buy" consensus rating and an average price target of $42.22, the stock fell 4.6% following the transaction.
Form 4 Xencor Inc: Richard J. Ranieri (Director) For: 10 November
This article reports on a Form 4 filing for Xencor Inc, indicating that Director Richard J. Ranieri made a transaction on November 10th. The filing details are not provided in the snippet, but the article focuses on this insider trading disclosure. Xencor Inc's stock (XNCR) is noted to have decreased by 4.60%.
At $39.82 a share, Xencor (XNCR) CFO sells 10,100 shares.
Xencor's Senior Vice President and CFO, Bart Jan Cornelissen, sold 10,100 shares of common stock at $39.82 per share on November 11, 2026. Following this transaction, he directly holds 65,798 shares. The sale was not conducted under a Rule 10b5-1 plan, as detailed in an SEC Form 4 filing.
Xencor Director Sold Shares Worth Over $3.1M
Xencor Director Richard J. Ranieri sold 81,252 shares of Xencor common stock in two transactions, totaling $3,189,435 at weighted average prices of $39.20 and $39.59 per share. Following these transactions, Ranieri directly holds 18,514 shares. This information is based on an SEC Form 4 filing.
A proposed 10,100-share sale at Xencor (XNCR) includes 9,216 shares from vested stock awards.
Xencor Inc. officer Bart Jan Cornelissen has proposed selling 10,100 common shares, valued at approximately $402,182, with an anticipated sale date of November 11, 2026. The shares consist of 884 acquired through an ESPP purchase and 9,216 from restricted stock vesting. The Form 144 filing indicates 75,039,689 shares outstanding for the company.
Xencor, Inc. (XNCR) stock price, news, quote and history
This article provides a detailed financial overview of Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company. It includes current stock price, market performance, key financial metrics, a company overview highlighting its drug development pipeline for cancer and autoimmune diseases, recent news, and analyst ratings. The report indicates a strong year-to-date and 1-year return for XNCR, significantly outperforming the S&P 500.
Xencor (XNCR) Is Drawing Fresh Attention, But What Is The Market Weighing?
Xencor (XNCR) has gained significant market attention after releasing positive early Phase 1b data for plamotamab in rheumatoid arthritis and an update on its autoimmune candidate XmAb657. This news has led to substantial share price increases, with a 59.62% return over 30 days and 177.76% over one year, alongside a recent swing to quarterly profitability. While some analysts see the stock as 6% undervalued with a fair value of $42.50, others caution about its P/S ratio of 15x, which is higher than the industry average of 9.7x, indicating potential valuation risk.
Early Arthritis Data Could Be A Big Test For Xencor Stock (XNCR)
Xencor (XNCR) reported third-quarter 2026 net income but still shows a year-to-date net loss, highlighting the cost of its research programs. Initial Phase 1b data for plamotamab in rheumatoid arthritis demonstrated deep B-cell depletion and reduced disease activity, suggesting the company's bispecific platform could expand into autoimmune conditions beyond oncology. This early data is crucial for shaping the investment narrative and testing the platform's ability to produce differentiated autoimmune therapies in competitive fields.
Plamotamab Trial Data Could Be A Game Changer For Xencor Stock (XNCR)
Xencor (XNCR) reported a net income of US$39.44 million for Q3 2026, alongside initial Phase 1b plamotamab data in rheumatoid arthritis and an updated timeline for XmAb657. The positive early signals from the plamotamab trial suggest Xencor's bispecific platform has potential beyond oncology, supporting a broader pipeline. Investors are now focused on the company's ability to translate this growing autoimmune toolkit into late-stage programs and justify its current market premium.
XNCR: Xencor director Richard Ranieri plans to sell 81,252 shares
Xencor director Richard Ranieri has filed a notice to sell 81,252 XNCR shares, valued at approximately $3.19 million, following an option exercise. The proposed sale, anticipated around November 10, 2026, could add selling pressure to the stock. The shares originated from restricted stock vesting in 2024 and 2025, and a stock option exercise.
XNCR: Xencor director Richard Ranieri plans to sell 81,252 shares
Xencor director Richard Ranieri has filed a notice to sell 81,252 XNCR shares, valued at approximately $3.19 million, following an option exercise and restricted stock vesting. This proposed sale, occurring around November 10, 2026, could potentially introduce selling pressure on the stock. The shares originate from restricted stock vesting in 2024 and 2025, and a stock option exercise paid in cash.
Xencor reports early plamotamab data in rheumatoid arthritis trial
Xencor, Inc. presented initial Phase 1b data for plamotamab in rheumatoid arthritis, showing significant B-cell reduction and clinical improvements in higher dose cohorts with manageable side effects. Additionally, the company provided an update on its XmAb657 study, indicating plans to enroll patients with severe autoimmune diseases in early 2027. Xencor's stock (NASDAQ: XNCR) saw a 9.62% increase.
Xencor Presents Initial Plamotamab Data in Rheumatoid Arthritis at ACR Convergence 2026 and Updates Progress in First-in-Human Study of XmAb657
Xencor announced initial Phase 1b data for plamotamab in rheumatoid arthritis, showing deep B-cell depletion and preliminary disease activity improvements in higher-dose cohorts. The company also provided an update on XmAb657, a bispecific T-cell engager, which demonstrated dose-dependent B-cell reductions in healthy participants, with patient enrollment planned for early 2027. These investigational therapies aim to reset the immune system for sustained disease control in severe autoimmune diseases.
Wall Street Zen Upgrades Xencor (NASDAQ:XNCR) to Buy
Wall Street Zen upgraded Xencor (NASDAQ:XNCR) from "hold" to "buy" after the biopharmaceutical company reported strong quarterly earnings, beating analyst expectations with $0.50 EPS and $116.52 million in revenue. Despite mixed analyst views, Xencor currently holds a "Moderate Buy" rating with an average price target of $42.22, and its shares have seen a significant increase, opening at $35.75 and nearing a one-year high.
A passive holder reports 9.88 million Xencor (XNCR) shares in an ownership amendment.
PRIMECAP Management Co. has reported a 13.29% passive stake in Xencor Inc. (XNCR) through an amended beneficial ownership filing. As of September 30, 2026, PRIMECAP beneficially owned 9,879,855 common shares, with sole voting and dispositive power over these shares. The PRIMECAP Odyssey Aggressive Growth Fund was specifically identified as having an interest exceeding 5% of Xencor's outstanding common stock.
Xencor Reports Third Quarter 2026 Financial Results
Xencor, Inc. reported its financial results for the third quarter ended September 30, 2026, highlighting progress across its clinical-stage pipeline for cancer and autoimmune diseases. Key updates include compelling clinical data for XmAb819 in advanced clear cell renal cell carcinoma, upcoming presentations for plamotamab in rheumatoid arthritis, and on-track development for TL1A-targeting programs XmAb942 and XmAb412. The company also detailed significant milestones achieved with partners Amgen, Astellas, and Zenas BioPharma, and reported a net income of $39.4 million for the quarter.
Xencor Reports Q3 2026 Total Assets Decline to $770.5 Million
Xencor, Inc. (NASDAQ:XNCR) filed its Q3 2026 10-Q report, revealing a decline in total assets to $770.5 million as of September 30, 2026, down from $875.5 million at the end of 2025. The report highlighted a significant decrease in marketable equity securities, while cash and accounts receivable saw modest increases. The company also noted 75,039,689 shares outstanding as of October 30, 2026, and flagged risks related to a prior restatement of financial statements.
Xencor Q3 Results: EPS $0.50 beats estimate, sales jump 455%
Xencor reported strong Q3 results, with EPS of $0.50 significantly beating the consensus estimate of $(0.73), marking a 725% increase from the prior year's loss. Quarterly sales surged by 454.86% year-over-year to $116.52 million, also surpassing analyst expectations. This performance suggests significant contributions from operational leverage or non-operating income, beyond just volume-driven revenue growth.
Xencor stock hits 52-week high at 33.62 USD
Xencor Inc. (XNCR) shares reached a 52-week high of $33.62, representing a 132.99% increase over the past year. This surge is attributed to strong investor confidence and positive analyst ratings, particularly for its XmAb819 kidney cancer drug, despite InvestingPro data suggesting the stock is overvalued and potentially in overbought territory. Analysts from Truist Securities, Wells Fargo, and RBC Capital have all raised their price targets for Xencor, citing compelling data from drug trials.
Xencor stock hits 52-week high at 33.62 USD By Investing.com
Xencor Inc.'s stock reached a new 52-week high of $33.62, marking a 132.99% increase over the past year. This surge is fueled by strong investor confidence and positive analyst updates for its XmAb819 drug for kidney cancer, with Truist Securities, Wells Fargo, and RBC Capital all raising their price targets. Despite being considered overvalued by InvestingPro, technical signals indicate the stock is in overbought territory, suggesting investors should monitor it closely.
Technical Reactions to XNCR Trends in Macro Strategies
This article provides a technical analysis of Xencor Inc. (NASDAQ: XNCR), highlighting strong sentiment across all time horizons supporting an overweight bias. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop loss levels. The analysis also includes multi-timeframe signal strengths and key support/resistance levels.
How Kidney Cancer Trial Progress At Xencor (XNCR) Has Changed Its Investment Story
Xencor (XNCR) recently provided updated Phase 1 data for XmAb819 in advanced clear cell renal cell carcinoma, including the selection of a 400 mcg/kg IV Phase 3 dose. This development shifts Xencor's investment narrative by adding a significant late-stage pipeline asset and emphasizing the company's trial execution capabilities, despite ongoing unprofitability and high R&D costs. The decision to advance to a global randomized trial and potential accelerated approval discussions indicates a major test for Xencor's bispecific antibody platform.
Vanguard updates its passive Xencor (XNCR) stake, with voting power over 507,754 shares.
Vanguard Capital Management reported an updated passive stake of 4.99% in Xencor Inc (XNCR), holding beneficial ownership of 3,710,894 common shares as of September 30, 2026. This includes sole voting power over 507,754 shares and sole dispositive power over all 3,710,894 shares. The filing, an amended Schedule 13G/A, indicates that Vanguard's holdings were acquired and are held in the ordinary course of business, not for influencing control of the issuer.
Xencor, Inc. (XNCR) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for Xencor, Inc. (XNCR), showing the average monthly price return from 2016 to 2026. It includes current stock prices and after-hours trading information for XNCR. The page also features general market data for Canadian, US, European, and Asian markets, along with cryptocurrency, commodity, and currency rates.
Xencor, Inc. (XNCR)
This page provides a detailed overview of Xencor, Inc. (XNCR), a biotechnology company. It includes key financial metrics such as market cap, revenue, dividend yield, and 52-week trading range. The page also highlights insider activity, specifically mentioning Ken Griffin's Citadel Advisors holdings in XNCR.
RBC Capital maintains Outperform rating on Xencor, $43 price target
RBC Capital has reaffirmed its Outperform rating on Xencor's stock, raising its price target to $43.00, which suggests a 47.4% upside from its previous close. This positive outlook is driven by strong clinical data for XmAb819, showing efficacy in renal cell carcinoma, and a robust pipeline of engineered antibody therapeutics for oncology and autoimmune diseases. The company's strategic focus on proprietary asset development further supports the increased valuation.
Xencor, Inc. (XNCR) PT Raised to $40 at Truist Securities
Truist Securities analyst Gregory Renza raised the price target on Xencor, Inc. (NASDAQ: XNCR) to $40 from $29, while maintaining a Buy rating. This increase follows XmAb819's compelling ESMO showing and investor call, with the analyst noting a 45.5% cORR and 82% 6-month PFS in ccRCC patients. The analyst believes XmAb819 is a credible novel therapy with manageable safety, supporting potential accelerated approval discussions in 1H27 and raising peak sales estimates to $1.1 billion.
Xencor stock surges on positive cancer drug trial data
Xencor Inc (NASDAQ:XNCR) shares surged 24% following the presentation of positive Phase 1 dose selection data for XmAb819, a bispecific T-cell engager for advanced clear cell renal cell carcinoma and ENPP3+ tumors. The company selected 400 mcg/kg as the proposed Phase 3 dose, demonstrating a 45.5% confirmed objective response rate and 82% 6-month progression-free survival. Xencor plans to discuss accelerated approval with the FDA and initiate a global randomized study by late 2027.
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
Xencor announced updated Phase 1 results for XmAb819, an ENPP3 x CD3 T-cell engager, in advanced clear cell renal cell carcinoma (ccRCC) patients, selecting 400 mcg/kg as the proposed recommended Phase 3 dose. The data showed impressive antitumor activity and tolerability in heavily pre-treated patients, with Xencor planning to discuss an accelerated approval pathway with the FDA and initiate a global randomized study. The company is also exploring XmAb819 in other ENPP3-expressing tumors and combination therapies.
Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer
Xencor announced updated Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma, showing a 45.5% objective response rate at the 400 microgram-per-kilogram dose. The company has selected this dose for planned Phase 3 development and intends to discuss accelerated approval and a randomized study with the FDA in the first half of 2027. Safety concerns like cytokine release syndrome and rash were manageable, largely low-grade, and self-limited.
Why Is Xencor Stock Trading Higher Today? - Xencor (NASDAQ:XNCR)
Xencor Inc. (NASDAQ: XNCR) shares are trading higher after the company presented updated Phase 1 study results for XmAb819 in advanced clear cell renal cell carcinoma (ccRCC) at the ESMO Congress 2026. The drug demonstrated robust response rates and favorable safety, leading William Blair analysts to praise its "unprecedented profile." Xencor plans to advance XmAb819 into late-stage testing and explore accelerated approval pathways with the FDA.
Xencor stock hits 52-week high at 32.29 USD
Xencor Inc.'s stock recently reached a 52-week high of $32.29, currently trading at $32.83, indicating strong market performance and investor confidence with a 90.61% return over the past year. Truist Securities also raised its price target for Xencor to $29 from $27, maintaining a Buy rating ahead of an important update regarding XmAb819 at the ESMO event. Despite appearing overvalued by InvestingPro, these developments highlight potential growth prospects for the biotech company.
Xencor Shares Climb 23.94% on XmAb819 Kidney Cancer Results
Xencor shares surged by 23.94% following positive results from a Phase 1 trial of XmAb819, a drug for advanced kidney cancer. The study demonstrated a 45.5% response rate, leading Xencor to plan accelerated discussions with the FDA. This rise occurred against a mixed U.S. market backdrop, with futures steadying after recent declines.
Xencor reports 45.5% confirmed response at selected kidney-cancer dose
Xencor (NASDAQ: XNCR) announced Phase 1 results showing a 45.5% confirmed tumor shrinkage rate in 11 evaluable kidney-cancer patients at a selected dose of 400 micrograms per kilogram for its experimental antibody, XmAb819. The company plans to discuss a potential accelerated approval pathway with the FDA in the first half of 2027 and initiate a global randomized study next year. Despite severe treatment-related adverse events in 72.1% of patients across expansion cohorts, the results support dose selection for future development.
Xencor, Inc. Estimates – NASDAQ:XNCR
This page provides financial actuals and estimates for Xencor, Inc. (NASDAQ:XNCR), allowing users to explore reported financial data and analyst estimates across various statements and metrics. It enables comparison of actual results with average, high, and low estimates, and visualization of trends over time, covering income statements, balance sheets, and cash flow on both annual and quarterly bases.
Xencor stock: Wedbush keeps USD 30.00 target for Xencor stock
Wedbush has reaffirmed its USD 30.00 price target for Xencor stock, following the company's strong second-quarter revenue of USD 51.22 million, significantly exceeding analyst consensus. Investors are anticipating upcoming clinical data from Xencor's XmAb819 program, with a presentation scheduled for October 25, 2026, and a webcast on October 26, 2026, which are expected to be key catalysts for the biotechnology company. Xencor's market capitalization stands at USD 1.9 billion, with its valuation heavily influenced by its pipeline data.
Xencor's (XNCR) Outperform Rating Reaffirmed at Wedbush
Wedbush has reiterated its "Outperform" rating for Xencor (NASDAQ:XNCR), setting a price target of $30.00, which implies a 19.24% upside from its previous close. This positive sentiment is shared by other analysts, resulting in a consensus "Moderate Buy" rating and an average price target of $34.00. The biopharmaceutical company recently exceeded quarterly earnings expectations, reporting a $0.29-per-share loss against a projected $0.80 loss, and revenues of $51.22 million.
Xencor (XNCR) Following XmAb819 Webcast Plans, Is The Pipeline Narrative Starting To Look Undervalued?
Xencor (XNCR) is gaining investor attention following plans for an October 26 webcast to discuss Phase 1 data for its XmAb819 kidney cancer program and outline a 2027 registration study. The stock has seen significant rallies recently, suggesting strong momentum around its pipeline. While Simply Wall St's narrative pegs Xencor as 21% undervalued, potential risks like underwhelming data or increased competition could impact its future.
Xencor (XNCR) Following XmAb819 Webcast Plans, Is The Pipeline Narrative Starting To Look Undervalued?
Xencor (XNCR) is gaining investor attention ahead of an October 26 webcast detailing Phase 1 data for its XmAb819 kidney cancer program and plans for a 2027 registration study. The company's stock has seen significant rallies, reflecting strong momentum around its antibody pipeline. Despite a valuation suggesting it's 21% undervalued at $31.42 per share, potential risks include underwhelming data or intense competition in the TL1A space.
Xencor schedules XmAb819 webcast: Wells Fargo targets Xencor stock at USD 30
Xencor is set to host a webcast on October 26, 2026, to discuss Phase 1 results for XmAb819, an experimental treatment for advanced clear cell renal cell carcinoma, following an oral presentation at the European Society for Medical Oncology Congress on October 25, 2026. Wells Fargo has maintained a Buy rating for Xencor stock with a price target of USD 30.00. The company's stock was valued at USD 1.7 billion on October 19, 2026, with a Nasdaq closing price of USD 23.19.
Wells Fargo Initiates Xencor(XNCR.US) With Buy Rating, Announces Target Price $30
Wells Fargo has initiated coverage of Xencor (XNCR.US) with a Buy rating. The firm has set a target price of $30 for the company's stock. This initiation suggests a positive outlook from Wells Fargo on Xencor's future performance.